COVID-19 trilogy: ARDS, inflammation and coagulopathy.
- Funded by Canadian Institutes of Health Research (CIHR)
- Total publications:1 publications
Grant number: 172632
Grant search
Key facts
Disease
COVID-19Start & end year
20202020Known Financial Commitments (USD)
$169,968.75Funder
Canadian Institutes of Health Research (CIHR)Principal Investigator
Louis FlamandResearch Location
CanadaLead Research Institution
CHU de QuébecResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Immunity
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
The current SARS-CoV-2 epidemic has taken the world by surprise at the end of 2019. TH virus is highly transmittable and causes severe infections mostly in elderly and people with comorbidities such as diabetes, high blood pressure and cardia disease. The most evident medical complication initially reported and associate with the infection is acute respiratory disease syndrome (ARDS). Recent data clearly indicates that in addition to the lungs, other organs such as the heart and kidneys are affected by the infection. One common finding is the presence of blood clots in veins and arterioles of patients, pointing out to a deregulated coagulation process. In addition to study the inflammation during SARS-CoV-2 infection, our goal is to understand why such blot clots are formed. We will be using different mouse models to address how platelets may get activated and from undersized blood clots. Lastly, we will explore the potential benefits of administrating anti-platelet and anti-coagulant drugs to mice in oder to protect them from the disease.
Publicationslinked via Europe PMC
Last Updated:a day ago
View all publications at Europe PMC